+1-888-308-5802      . .

Novartis announces Kymriah’s EU approval for blood cancer treatment

Author : Pankaj Singh | Published Date : 2018-08-27 

Novartis announces Kymriah’s EU approval for blood cancer treatment

Novartis International AG has reportedly announced that it has received approval for its cancer therapy called Kymriah, issued by the European Commission. The approved gene-modifying treatment will be used initially to treat young adults up to 25 years of age suffering with B-Cell acute lymphoblastic leukemia and adult patients down with diffuse large B-cell lymphoma.

The one-time therapy that’s said to treat blood cancer by fighting T-cells in the patient’s system, will supposedly modify their bodies to fight off bad cells and then re-infuse new cells. The treatment is also approved in both indications in the United States.

According to sources close to the development, with an investment of $90.39 million Novartis will establish more facilities to continue manufacturing Kymriah. The pharma claimed therapy will cost about $475,000 for patients with acute lymphoblastic leukemia and $373,000 for patients afflicted with diffuse large B-cell lymphoma.

Formerly, Novartis had gained appreciation for its groundbreaking work pertaining to therapy exclusively for dying patients who didn’t respond to other drugs. However, officials were aghast by the prices, which apparently makes Kymriah one of the most expensive treatments.

In the United States, Novartis will only accept charges if patients with lymphoblastic leukemia show signs of recovery by the end of the first month. Meanwhile, discussions in terms of European pricing are still in progress.

In a statement to sources, Novartis revealed that Kymriah’s availability will differ for each country, based on factors like the establishment of licensed facilities for the appropriate indications and completion of a fixed payment agreement.

Post its launch in the United States, the treatment earned $28 million in sales, which is estimated to surpass $1 billion as soon as the demand begins to grow. In the meantime, the pharma firm plans to commence therapies to European patients at least by 2020.

About Author

Pankaj Singh . .

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Samsung to roll out Galaxy S23 with faster, sustainable features

Samsung to roll out Galaxy S23 with faster, sustainable features

Published Date: 2023-02-03         Author: Pankaj Singh

Samsung Electronics, the South Korean technology giant, has reportedly introduced its flagship Galaxy S23 smartphone range on Wednesday, describing it as the most robust S series yet, inclusive of improved camera features, faster, and environmental-friendly features. Around 2,000 journalists and ... Read More>>

U.S. posts robust economic growth in Q4 2022 amid rising borrowing costs

U.S. posts robust economic growth in Q4 2022 amid rising borrowing costs

Published Date: 2023-01-27         Author: Pankaj Singh

The U.S. economy reportedly expanded more rapidly than anticipated in Q4, but this likely overstates the country's health considering a measure of domestic demand that surged at its weakest pace in two and a half years, highlighting the impact of increased borrowing costs. The early fourth-qu... Read More>>

North Korea pledges to get its economy on track after COVID disruption

North Korea pledges to get its economy on track after COVID disruption

Published Date: 2023-01-20         Author: Pankaj Singh

North Korea has reportedly committed to revitalizing industrial output and returning the economy to ‘normalcy’ following the disruption created by the COVID-19 outbreak. As per reports, the Korean Central News Agency (KCNA) stated on Thursday that the principal responsibility of North... Read More>>

© 2023 Fractovia. All Rights Reserved